sivelestat has been researched along with transforming growth factor alpha in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hihara, J; Konishi, K; Mizuiri, H; Suzuki, T; Tanabe, K; Taomoto, J; Ukon, K; Wada, Y; Yoshida, K | 1 |
| Hamai, Y; Hihara, J; Mizuiri, H; Oeda, M; Sanada, Y; Shigematsu, H; Suzuki, T; Tanabe, K; Tsutani, Y; Ukon, K; Wada, Y; Yoshida, K | 1 |
| Futamura, M; Kawaguchi, Y; Morimitsu, K; Nawa, M; Nonaka, K; Osada, S; Yoshida, K | 1 |
3 other study(ies) available for sivelestat and transforming growth factor alpha
| Article | Year |
|---|---|
Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha.
Topics: Animals; Carcinoma; ErbB Receptors; Female; Glycine; Humans; Leukocyte Elastase; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 3; Neoplasm Transplantation; Phosphorylation; Serine Proteinase Inhibitors; Stomach Neoplasms; Sulfonamides; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2006 |
Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines.
Topics: Cell Growth Processes; Cell Line, Tumor; Cell Movement; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Glycine; Humans; Leukocyte Elastase; MAP Kinase Signaling System; Platelet-Derived Growth Factor; Sulfonamides; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A | 2007 |
Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glycine; Humans; Leukocyte Elastase; Receptor, ErbB-2; Serine Proteinase Inhibitors; Signal Transduction; Sulfonamides; Transforming Growth Factor alpha; Trastuzumab | 2012 |